Elisabeth Sörstadius

627 total citations
21 papers, 408 citations indexed

About

Elisabeth Sörstadius is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Nephrology. According to data from OpenAlex, Elisabeth Sörstadius has authored 21 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Cardiology and Cardiovascular Medicine and 5 papers in Nephrology. Recurrent topics in Elisabeth Sörstadius's work include Diabetes Treatment and Management (9 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Medication Adherence and Compliance (4 papers). Elisabeth Sörstadius is often cited by papers focused on Diabetes Treatment and Management (9 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Medication Adherence and Compliance (4 papers). Elisabeth Sörstadius collaborates with scholars based in Sweden, United Kingdom and United States. Elisabeth Sörstadius's co-authors include Juan José García Sánchez, Glen James, Stephen Nolan, Eric Wittbrodt, Anna Bobrowska, Roberto Pecoits‐Filho, Katherine R. Tuttle, Klas Bergenheim, J. Næsdal and Stephen D. Pratt and has published in prestigious journals such as Gastroenterology, PLoS ONE and Nephrology Dialysis Transplantation.

In The Last Decade

Elisabeth Sörstadius

21 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elisabeth Sörstadius Sweden 10 155 119 102 63 56 21 408
Teresa M. Kimes United States 12 141 0.9× 64 0.5× 165 1.6× 39 0.6× 85 1.5× 20 503
Jedidiah I Morton Australia 12 268 1.7× 41 0.3× 63 0.6× 67 1.1× 116 2.1× 58 460
Una Ørvim Sølvik Norway 11 122 0.8× 42 0.4× 58 0.6× 21 0.3× 99 1.8× 32 516
Gail T. Louis United States 6 87 0.6× 80 0.7× 300 2.9× 45 0.7× 107 1.9× 9 473
Seyed Mehrdad Hamrahian United States 8 41 0.3× 67 0.6× 155 1.5× 28 0.4× 28 0.5× 11 346
Anca Ka Chun Chan Hong Kong 17 284 1.8× 151 1.3× 115 1.1× 115 1.8× 59 1.1× 29 631
Heide A. Stirnadel-Farrant United Kingdom 11 126 0.8× 137 1.2× 61 0.6× 22 0.3× 77 1.4× 34 526
Daniele Ugo Tari Italy 15 39 0.3× 81 0.7× 37 0.4× 100 1.6× 41 0.7× 30 499
Alain Gay Germany 11 183 1.2× 75 0.6× 146 1.4× 31 0.5× 89 1.6× 22 369
Min Zhuo United States 16 270 1.7× 215 1.8× 100 1.0× 58 0.9× 123 2.2× 38 764

Countries citing papers authored by Elisabeth Sörstadius

Since Specialization
Citations

This map shows the geographic impact of Elisabeth Sörstadius's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabeth Sörstadius with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabeth Sörstadius more than expected).

Fields of papers citing papers by Elisabeth Sörstadius

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabeth Sörstadius. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabeth Sörstadius. The network helps show where Elisabeth Sörstadius may publish in the future.

Co-authorship network of co-authors of Elisabeth Sörstadius

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabeth Sörstadius. A scholar is included among the top collaborators of Elisabeth Sörstadius based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabeth Sörstadius. Elisabeth Sörstadius is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pouvourville, Gérard de, et al.. (2023). Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective. Advances in Therapy. 40(9). 3751–3769. 3 indexed citations
2.
Lam, Carolyn S.P., Robert Wood, Muthiah Vaduganathan, et al.. (2021). Contemporary economic burden in a real‐world heart failure population with Commercial and Medicare supplemental plans. Clinical Cardiology. 44(5). 646–655. 17 indexed citations
3.
Darlington, Oliver, Marc Evans, Phil McEwan, et al.. (2021). Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review. Advances in Therapy. 38(2). 994–1010. 40 indexed citations
4.
Sánchez, Juan José García, Juliette C. Thompson, David A. Scott, et al.. (2021). Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials. Advances in Therapy. 39(1). 193–220. 22 indexed citations
5.
Darlington, Oliver, et al.. (2021). MO876ESTIMATING THE BUDGET IMPACT OF DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE FROM A UK PAYER PERSPECTIVE*. Nephrology Dialysis Transplantation. 36(Supplement_1). 3 indexed citations
6.
Sörstadius, Elisabeth, et al.. (2020). Humanistic burden and economic impact of heart failure – a systematic review of the literature. F1000Research. 8. 859–859. 8 indexed citations
7.
Bobrowska, Anna, Juan José García Sánchez, Glen James, et al.. (2020). Burden of Chronic Kidney Disease by KDIGO Categories of Glomerular Filtration Rate and Albuminuria: A Systematic Review. Advances in Therapy. 38(1). 180–200. 111 indexed citations
8.
Darlington, Oliver, et al.. (2020). SAT-142 THE ECONOMIC AND PATIENT BURDEN OF CHRONIC KIDNEY DISEASE (CKD): RESULTS FROM AN INTERNATIONAL CKD POLICY EVALUATION. Kidney International Reports. 5(3). S60–S61. 1 indexed citations
9.
Sánchez, Juan José García, Elisabeth Sörstadius, Oliver Darlington, et al.. (2020). P0773ESTIMATING THE BURDEN OF CHRONIC KIDNEY DISEASE (CKD) IN THE UK: COMPARISON OF TWO HEALTH ECONOMIC POLICY ANALYSIS METHODS. Nephrology Dialysis Transplantation. 35(Supplement_3). 1 indexed citations
10.
11.
Sörstadius, Elisabeth, et al.. (2019). Humanistic burden and economic impact of heart failure – a systematic review of the literature. F1000Research. 8. 859–859. 6 indexed citations
12.
Osei-Assibey, George, et al.. (2018). SP301THE ECONOMIC BURDEN OF CHRONIC KIDNEY DISEASE: FINDINGS FROM A SYSTEMATIC LITERATURE REVIEW. Nephrology Dialysis Transplantation. 33(suppl_1). i445–i445. 2 indexed citations
13.
Henriksson, Martin, et al.. (2016). A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus. PharmacoEconomics. 34(6). 569–585. 29 indexed citations
14.
Rydén, Anna, et al.. (2016). The Humanistic Burden of Type 1 Diabetes Mellitus in Europe: Examining Health Outcomes and the Role of Complications. PLoS ONE. 11(11). e0164977–e0164977. 27 indexed citations
15.
Henriksson, Martin, et al.. (2015). A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus. Value in Health. 18(7). A607–A607. 13 indexed citations
16.
Bytzer, Peter, Stephen D. Pratt, Eric P. Elkin, J. Næsdal, & Elisabeth Sörstadius. (2012). Burden of Upper Gastrointestinal Symptoms in Patients Receiving Low-Dose Acetylsalicylic Acid for Cardiovascular Risk Management. American Journal of Cardiovascular Drugs. 13(1). 27–35. 7 indexed citations
17.
Sörstadius, Elisabeth, Johan Herlitz, Emma Nauclér, & J. Næsdal. (2010). PGI19 PRESCRIPTION RATES AND ADHERENCE TO PROTON PUMP INHIBITOR THERAPY AMONG PATIENTS WHO REQUIRE LOW-DOSE ACETYLSALICYLIC ACID FOR CARDIOVASCULAR PREVENTION. Value in Health. 13(7). A372–A372. 3 indexed citations
18.
Pratt, Stephen D., et al.. (2010). The Impact of Upper Gastrointestinal Symptoms on Nonadherence to, and Discontinuation of, Low-Dose Acetylsalicylic Acid in Patients with Cardiovascular Risk. American Journal of Cardiovascular Drugs. 10(5). 281–288. 35 indexed citations
19.
Margolis, Mary Kay, Katarina Halling, Elisabeth Sörstadius, et al.. (2009). Upper Gastrointestinal Symptoms Experienced by Users of Low-Dose Aspirin (Acetylsalicylic Acid) [75–325 mg/day] for Primary and Secondary Coronary Artery Disease Prevention. Patient. 2(2). 89–93. 2 indexed citations
20.
Pratt, Stephen D., et al.. (2009). T1050 Dyspeptic Symptoms and Sleep Disturbance: A Report from a Large Observational Study in Low-Dose Acetylsalicylic Acid Users. Gastroenterology. 136(5). A–488. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Teresa M. Kimes Breakdown of academic impact, for papers by Jedidiah I Morton Breakdown of academic impact, for papers by Una Ørvim Sølvik Breakdown of academic impact, for papers by Gail T. Louis Breakdown of academic impact, for papers by Seyed Mehrdad Hamrahian Breakdown of academic impact, for papers by Anca Ka Chun Chan Breakdown of academic impact, for papers by Heide A. Stirnadel-Farrant Breakdown of academic impact, for papers by Daniele Ugo Tari Breakdown of academic impact, for papers by Alain Gay Breakdown of academic impact, for papers by Min Zhuo
Rankless by CCL
2026